Background. Use of the heptavalent pneumococcal conjugate vaccine ) has been associated with decreased a incidence of invasive pneumococcal disease (IPD) among children in the United States.
fectiveness of the vaccine may depend on the serogroup distribution among cases of IPD in a community. It is unclear whether serogroup distribution will change over time in response to selective pressure exerted by the vaccine. In children, serogroup replacement among isolates associated with carriage has been observed after immunization [4] , but the rate of IPD associated with such replacement has not been documented.
In the United States, serogroups represented in PCV7 are reported to account for 80%-97.7% of IPD cases among children [5] [6] [7] . Among Alaska Native children and Navajo children, PCV7 serogroups account for a smaller proportion of IPD cases than do nonvaccine serogroups [8, 9] . In studies from Europe, Latin America, Israel, and Australia, PCV7 serogroups accounted for fewer cases of IPD than did PCV7 serogroups in the United States; one reason for this is the increased proportion of IPD cases due to serogroup 1 [10] [11] [12] [13] [14] [15] [16] .
Elsewhere, we noted that a significant proportion of cases of IPD among children in Utah were due to non-PCV7 serogroups, especially serogroup 1 [17] . The purpose of this study was to identify the serogroups responsible for IPD in children in the intermountain west (IMW) and to examine temporal trends in the incidence of IPD, the proportion of infecting isolates that are resistant to antibiotics, and the serogroup distribution before and after the introduction of PCV7. We also compared the characteristics of IPD due to non-PCV7 serogroups with those of IPD due to PCV7 serogroups.
METHODS

Identification of invasive pneumococcal disease (IPD) in the Intermountain Health Care System (IHC).
We determined the incidence of IPD in a defined population in the IMW, using the records of the IHC, the largest nonprofit health care system in the region. The IMW includes Utah, Idaho, Montana, Wyoming, and parts of Arizona and Nevada. IHC operates Primary Children's Medical Center (PCMC) in Salt Lake City, Utah, a 250-bed children's hospital and the only pediatric tertiary care hospital in the region. We analyzed patterns of referral to the hospital between 1996-2003 using the Utah Hospital Discharge Database (Utah Department of Health, Office of Health Care Statistics) [18] . The internal review boards of the University of Utah and Intermountain Health Care approved this study.
All IHC facilities share a computerized record system, and data are stored in the Enterprise Data Warehouse (EDW). The EDW was queried for cases of IPD in children aged !18 years that were recorded during 1996-2003. International Classification of Disease, Ninth Revision (ICD-9), codes were specific for diseases caused by Streptococcus pneumoniae, including 038.2 and 790.7 (sepsis and/or bacteremia), 320.1 and 320.2 (meningitis), 481 (pneumonia), 510.9 (parapneumonic empyema), 567.1 (peritonitis), and 711.00 (abscess), all which had the 041 modifier (which indicates infection with S. pneumoniae).
Identification of children with IPD cared for at PCMC. We recovered and serogrouped all isolates of S. pneumoniae recovered from patients at PCMC between 1997-2003. Isolates from blood, CSF, and abscess, joint, pleural, or peritoneal fluid samples were serogrouped in duplicate (by E.O.M. and C.K.S.) by capsular swelling methods (Statens Seruminstitut and Daco) and the slide agglutination method (Denka Seiken) [19] . Antimicrobial susceptibility profiles were collected, penicillin susceptibility was defined using the Etest (AB Biodisk), and breakpoints were established by means of NCCLS criteria [20] . Genetic relatedness of serogroup 1 isolates was determined by multilocus sequence typing [21] .
Review of medical records. Medical records of patients with culture-confirmed IPD at PCMC were reviewed for demographic and clinical data. Classification of empyema was based on the Light criteria [16] . All patients who received a diagnosis of pneumonia or empyema had positive results of blood and/or pleural fluid cultures, with the exception of 3, whose diagnoses were made on the basis of positive results of bronchiolar alveolar wash culture. Serious IPD was defined as disease requiring hospitalization for 13 days, and life-threatening IPD was defined as disease resulting in admission to the pediatric intensive care unit, surgery, or death. Documentation of To test for statistical significance of trends over time, we used the binomial probability mid-P exact test for rate data [22] . The proportion of IPD cases due to PCV serogroups during the prevaccine period was compared to the proportion due to PCV serogroups during the postvaccine period. Fisher's exact test was used for statistical testing of hypotheses.
Temporal trends in the absolute number of cases of IPD for each serogroup were analyzed by random-effects, hierarchical (multilevel) Poisson regression using MlwiN software, version 2 (MlwiN). Serotypes were modeled as random effects by considering the observed serogroups as a sample of possible serogroups. This approach is superior to modeling serogroups as fixed effects, because it less vulnerable to unreliable variations from small serogroup-specific sample sizes [23] . The model was fit to 7 year-specific counts nested within each serogroup, with the data from the postvaccine period incorporated using a period indicator term in the model equation. Thus, the random terms were postvaccine period and intercept. The model was fit by the restricted iterated generalized least-squares method, and the postvaccine period coefficient for each serogroup, representing the level 2 residual and the level 2 comparative SD, was derived. Serogroup coefficients for which the 95% CI did not include the null value were considered to be associated with a statistically significant change. Coefficients were exponentiated to yield incidence rate ratios. An assumption of this analysis is that the underlying denominator of person-time experience that represented the pediatric population at risk for IPD (i.e., the referral base) was stable during the 7-year period.
We compared children with IPD due to PCV7 serogroups to children with IPD due to non-PCV7 serogroups. Comparisons of categorical data for different groups were performed by means of x 2 analysis or Fisher's exact test, as appropriate. For categorical variables with 12 categories, we used the FisherFreeman-Halton test, which is an extension of Fisher's exact test [24] . Continuous variables were analyzed with the 2-sample t test, if the normality assumption was verified by the ShapiroWilk test, or with Wilcoxon's rank-sum test, if the normality assumption was not verified. Significance tests of related categories or related subgroups were adjusted for multiplicity using Holm's P value-adjustment multiple comparison procedure [25] . The Pacific Islander race comparison was not adjusted for multiplicity as part of the race/ethnicity variable, because this comparison represented a separate, prespecified hypothesis to confirm previously published research [26] .
In the analysis of serogroup distribution and antibiotic resistance for isolates from children treated at PCMC, we used the period of 1997-2003. All P values are from a 2-sided comparison. A P value р.05 was considered to be statistically significant.
RESULTS
Trends in the IHC population.
The EDW contained data for 306,082-420,293 individual children each year, or ∼40% of the children in the IMW [27] . The total number of admissions to PCMC increased from 8890 to 11,040 between 1996 and 2003, reflecting growth in the child population in the IMW. However, the referral patterns to the hospital remained unchanged.
Between 1996 and 2003, a total of 1535 episodes of IPD were identified, including pneumonia (44% of episodes); parapneumonic empyema (22%); meningitis (12.5%); bacteremia (11.5%); abscess, arthritis, or osteomyelitis (9%); and peritonitis (!1%). The mean number of IPD cases at PCMC increased from 77 cases/year during 1996-2000 to 90 cases/year during 2001-2003; however, the percentage of hospital admissions associated with IPD did not change (0.85% and 0.9% of all admissions, respectively).
The overall incidence of IPD decreased 27% from the prevaccine years to the postvaccine years (55 vs. 41 cases/100,000 children;
). The total decrease was driven primarily by P ! .001 a 35% decrease among children 0-24 months of age (119 vs. 77 cases/100,000 children; ) ( figure 1 and table 1 ). De-P ! .001 creases in the incidence of bacteremia (6.9 vs. 4.6 cases/100,000 children;
) and pneumonia (31 vs. 16 cases/100,000 P p .02 children;
) and an increase in the incidence of para-P ! .001 pneumonic empyema (10.3 vs. 14.3 cases/100,000 children;
) were documented from the prevaccine period to the P p .013 postvaccine period. The incidence of meningitis remained constant (6.7 vs. 6 cases/100,000 children during the pre-and postvaccine periods, respectively;
). P p .49 Invasive pneumococcal disease in the PCMC cohort. A total of 234 children with culture-confirmed IPD were treated at PCMC during 1997-2003 (table 2) ; 223 were from Utah, 5 were from Idaho, 2 each were from Montana and Nevada, and 1 each was from Arizona and Wyoming. Ninety-nine percent of pneumococcal isolates were serogrouped, and 26 serogroups were identified (table 3) . The most common serogroups were 19 (15% of isolates), 14 (11%), 6 (11%), 9 (9%), and 1 (9%). A total of 146 isolates (62%) were from serogroups included in the PCV7 vaccine (i.e., serogroups 4, 6, 9, 14, 18, 19, and 23) (table 3) .
Temporal trends of IPD in the PCMC cohorts. The number of cases of IPD classified as occult bacteremia decreased from 18 (14%) of 129 in the prevaccine years to 5 (5%) of 105 in the postvaccine years ( ), whereas the number clas-P p .018 sified as empyema during these periods increased from 21 (16%) of 129 to 31 (30%) of 105 ( ) ( Comparison of IPD caused by PCV7 with IPD caused by non-PCV7 serogroups. Children with IPD due to non-PCV7 serogroups were less likely to have penicillin-resistant infecting isolates or bacteremia and more likely to have parapneumonic empyema than were children with IPD due to PCV7 serogroups (table 5) . Although the mean age of children with non-PCV7 disease was higher than that for children with PCV7 disease, nearly equal numbers of children were aged р24 months and 124 months (45 vs. 41); 19 children had non-PCV7 disease in the first year of life, and 10 others had non-PCV7 disease in the first 3 months of life. Children with disease due to non-PCV7 serogroups had similar rates of intensive care, surgery, and death but had longer hospital stays than did children with disease due to vaccine serogroups.
Immunization with PCV7 in children with IPD. None of the 92 children treated for IPD at PCMC during 1997-1999 had received PCV7. Verification of PCV7 vaccination status was obtained for 62 (44%) of 142 children with IPD who were treated during 2000-2003. Ten (16%) had received at least 1 dose of PCV7 and 8 had received 11 before developing IPD. Serogroups could be determined for 9 children. Five had disease due to PCV7 serogroups; 1 child was immunocompromised, 15 (7) 9 (7) 6 (6) 4 8 (3) 6 (5) 2 (2) Non-PCV7 1 21 (9) 10 (8) 11 (10) 3 11 (5) 1 (!1) 10 (10) and 2 had a history of trauma. In the other 4 children, all of whom were aged 2-27 months and previously healthy, disease was due to a non-PCV7 serogroup, including illness in a 13-month-old infant who received 3 doses of PCV7 and died from meningitis due to serogroup 15.
DISCUSSION
In the IMW, introduction of PCV7 was associated with a 27% reduction in the incidence of IPD among children !18 years of age and a 35% reduction in the incidence among children !2 years of age. The proportion of infections due to penicillinnonsusceptible strains decreased. By 2003, there was a 40% reduction in the number of invasive infections due to vaccine serogroups. However, the number of cases of IPD due to nonvaccine serogroups increased significantly. The majority of cases of IPD occurred in unvaccinated individuals. However, striking changes in serogroup distribution, possibly related to vaccination rates in the community, were observed. Surveillance in Utah indicated that, in the years immediately before the introduction of PCV7, ∼70% of the cases of IPD in children were due to PCV7 serogroups, which contrasts with the incidences reported for other regions in the United States [8, [28] [29] [30] . Prolonged surveillance in Boston demonstrated an unchanging serogroup distribution in the prevaccine era [31] . However, introduction of a vaccine that induces immunity against specific serogroups in young children would be expected to alter the epidemiologic properties of IPD.
In the year after the introduction of PCV7, the Centers for Disease Control and Prevention Active Bacterial Core (ABC) sites reported a 69% decrease in the rate of IPD for children 0-24 months of age [3] . Data from 2002 document that the rate of IPD among children !2 years of age was 34.8 cases/ 100,000 children, compared with a mean rate of 188 cases/ 100,000 children during 1997-2000, for a decrease of 81% [32] . Similarly, a consortium of US pediatric hospitals reported a 66% decrease in the rate of IPD in 2002 among children aged 0-24 months [33] .
In the IHC population, we noted a 35% decrease in the incidence of IPD among children 0-24 months of age. This is an important improvement, but it is modest compared with data published elsewhere [3, 32, 33] . The rates of IPD we observed among young children remain 2-7 times the rates reported by the ABC sites, despite similar or lower rates during the prevaccine period [32] . Non-PCV7 26 (20) 46 (44) !.001
Nontypeable or no growth 9 (7) 7 (7) Not significant NOTE. PCV7, heptavalent pneumococcal vaccine. a Pacific Islander race was tested separately from the race variable, because it was a prespecified hypothesis. b Adjusted for multiple (4) comparisons using Holm's procedure.
Vaccine uptake may influence effectiveness. The National Immunization Survey reports that 54.5% of Utah children receive 3 doses of PCV7 by the age of 35 months [34] . This is similar to the national average of 59.1%, but it is lower than the percentages for states with ABC sites (median, 62.3%) [34] . The importance of non-PCV7 strains in the prevaccine years, including an established clone of serogroup 1 [17] , may have allowed accelerated spread of these strains under selective pressure. Utah has a larger number of children per household than any other state in the United States, and household crowding may facilitate spread and allow for more-rapid recognition of serogroup emergence.
We observed not only a marked decrease in the proportion of cases of IPD due to PCV7 serogroups (from 73% during 1997-2000 to 50% during [2001] [2002] [2003] , but also a marked increase in the absolute number of invasive infections due to serogroups not included in the vaccine. The significant decrease in the proportion of cases of IPD due to serogroup 14 isolates, which are the common cause of pneumonia and occult bacteremia [5] , resulted in fewer cases of disease in the IHC population that was treated in community settings, but this decrease was accompanied by an increase in the number of cases of empyema treated at PCMC. Although IPD due to replacement serogroups could be documented in only 4 vaccinated children, it is possible that changes in serogroup distribution of strains that caused IPD in the postvaccine period reflects serogroup replacement of strains involved in carriage in the community as a result of immunization [35] .
The impact of PCV7 is apparent in the decreased rate of penicillin resistance among pneumococci, which is similar to the rate reported by others [36] . Although a decrease in the rate of antibiotic resistance is an important benefit of immunization, antibiotic resistance may not impact clinical outcomes [37] [38] [39] [40] [41] . Properties associated with a particular clonal or capsular type are likely to be important for determining both the potential of pneumococci to cause IPD and the type and severity of disease [42] .
Disease caused by isolates from non-PCV7 serogroups (which are more susceptible to penicillin than are PCV7 serogroup isolates) in our community was severe. Children with non-PCV7 infections had hospital stays nearly twice as long as children with IPD due to the PCV7 serogroups, in part because of the high rate of empyema. Other regions of the United States and the United Kingdom are reporting increases among children in the incidence of complicated pneumonia related to serotype 1 disease, specifically pneumonia caused by sequence type 227 [33, [43] [44] [45] [46] [47] [48] . We believe that surveillance for serotype 1 disease and strategies to prevent its further emergence in the United States will become increasingly important.
These findings have important implications for pneumococcal immunization strategies for children in the IMW and may be relevant to other regions with a high rate of IPD due to isolates from serogroup 1 or other non-PCV7 serogroups [8, 10, [49] [50] [51] [52] [53] [54] [55] . Several conjugate vaccine formulations with 9 and 11 antigens have been used experimentally [56] [57] [58] [59] . These preparations vary, but all contain antigens for serogroup 1 and should be evaluated for the containment of serogroup 1 disease. An alternative strategy might include the 23-valent pneumococcal polysaccharide vaccine in children aged у2 years after priming with conjugate vaccine in infancy. Children who have received PCV7 may have a better antibody response to the polysaccharide vaccine [60] [61] [62] .
Our study has several limitations. The population-based study is based on computerized records and coding, and misclassification may have occurred. It is unlikely, however, that this would influence the detection of temporal trends. Possible changes in referral patterns could have influenced the results of our study. However, evaluation of referral patterns revealed no changes during the study period. We could not document PCV7 vaccination status for 56% of children treated for IPD after PCV7 licensure, which limited our ability to confirm replacement disease. The microbiologically confirmed cases of IPD are subject to referral bias. Our data included only 23 children (10% of the total cohort) who had occult bacteremia. This is in contrast to other studies of serogroup distribution that have included significant numbers of cases of bacteremia without a focus [5, 29, 31] . Our serogroup analysis, however, represents the serogroups most likely to cause life-threatening disease and identifies serogroups that we would most hope to decrease the rate of infection through a successful immunization strategy. Finally, we performed serogrouping analyses rather than serotyping analyses. Thus, we grouped vaccine serotypes, such as 6B, with potentially cross-reactive nonvaccine serotypes, such as 6A. This may have led us to overestimate the number of vaccine serotypes in our cohorts.
Despite these limitations, we believe that the study demonstrates important changes in the epidemiologic properties of pediatric IPD since the introduction of PCV7. The potential impact of any pneumococcal vaccine will depend on the serogroup distribution of invasive strains before initiation of vaccination. The emergence of nonvaccine serogroups and IPD due to isolates from these serogroups may be more likely to occur as a result of selective pressure, if nonvaccine serogroups are prevalent at baseline. Disease caused by serogroups not contained in PCV7 may be severe, although antibiotic resistance is uncommon. Continued regional surveillance is needed to maximize the benefits of a pneumococcal immunization program.
